Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aldéric Fraslin

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
BMC Urology|May 12, 2025
Characteristics, management and survival outcomes in patients with muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup analysis from the coblance cohortAldéric Fraslin, Florian Colrat, Maryam Karimi, et al.
BMJ Open|December 21, 2023
Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of lifeThierry Lebret, Julia Bonastre, Aldéric Fraslin, et al.
The Lancet. Oncology|March 8, 2021
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trialJoël Guigay, Anne Aupérin, Jérôme Fayette, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
BMC Urology|May 12, 2025
Characteristics, management and survival outcomes in patients with muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup analysis from the coblance cohortAldéric Fraslin, Florian Colrat, Maryam Karimi, et al.
BMJ Open|December 21, 2023
Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of lifeThierry Lebret, Julia Bonastre, Aldéric Fraslin, et al.
The Lancet. Oncology|March 8, 2021
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trialJoël Guigay, Anne Aupérin, Jérôme Fayette, et al.
Pageof 1